Headlines about Harvard Bioscience (NASDAQ:HBIO) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Harvard Bioscience earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.1194985614701 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Harvard Bioscience (HBIO) opened at $3.75 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.87 and a current ratio of 3.40. The stock has a market cap of $134.29, a PE ratio of -41.67 and a beta of 1.00. Harvard Bioscience has a one year low of $2.25 and a one year high of $3.90.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.03. Harvard Bioscience had a negative net margin of 3.16% and a positive return on equity of 1.11%. The firm had revenue of $25.05 million for the quarter, compared to analysts’ expectations of $24.60 million. equities research analysts forecast that Harvard Bioscience will post 0.05 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Harvard Bioscience (HBIO) Receives Media Impact Score of 0.10” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/harvard-bioscience-hbio-receives-media-impact-score-of-0-10/1799507.html.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Insider Buying and Selling by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.